MMED earnings

Strong start to fiscal year with net sales of $843 million growing 17% as reported and 16% organicU.S. net sales growth accelerated to 13%; continued robust international net sales growth of 18% as reported, 17% organicAdvanced global pipeline ahead of schedule with FDA submission for MiniMed Fit™, CE Mark for MiniMed Flex™, Vivera™ FCL U.S. pivotal trial enrollment completion, and IDE approval for next-gen extended wear MiniMed sensorRaises fiscal year 2027 organic revenue growth guidanceNORTHRIDGE, Calif., Sept. 1, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today reported financial results for its first quarter (Q1) of fiscal year 2027 (FY27), ended

Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-yearRecord annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organicAdvanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDINORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026. "MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets